CELEA THERAPEUTICS WILL PRESENT PHASE 3 TRIAL DESIGN FOR IDIOPATHIC PULMONARY FIBROSIS AND KEY INSIGHTS FROM A DEUPIRFENIDONE DRUG-DRUG INTERACTION STUDY AT THE UPCOMING EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS

Reuters · 5d ago

Please log in to view news